Navigation Links
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
Date:3/26/2008

IRVINE, Calif., March 26 /PRNewswire-FirstCall/ -- NuRx Pharmaceutical Inc.'s (OTC Bulletin Board: NURX) next-generation rexinoid agonist, NRX4204, significantly reduced the number and size of lung tumors and lowered the total tumor volume in mouse models compared to the control group, according to a paper published in Clinical Cancer Research (2007; Vol. 13, Issue 20: 6237-6243).

In addition, the paper showed that NRX4204 caused marked tumor regression in all of the mammary tumors when used therapeutically. Rexinoids regulate cell proliferation, differentiation, and apoptosis pathways.

Entitled "A New Rexinoid, NRX4204, Prevents Carcinogenesis in Both Lung and Mammary Gland," the paper is based on a study that first evaluated the anti-inflammatory effects of NRX4204 and its growth-inhibitory properties in vitro and then measured the compound's ability to prevent and/or treat experimental lung and estrogen receptor (ER)-negative breast cancer in vivo.

"This study demonstrates that NRX4204 is exceptionally potent and not only reduces the number and size of adenocarcinomas in the lung, but it also prevents the development of mammary tumors and induces striking tumor regression in established mammary tumors," said Michael Sporn, Ph.D., professor of pharmacology and toxicology and of medicine at Dartmouth Medical School and the study's principal investigator. "For the first time, NRX4204 also showed effects as an anti-inflammatory agent in cell culture models that are highly relevant for human inflammatory diseases."

Harin Padma-Nathan, M.D., President and CEO of NuRx Pharmaceuticals said: "In this study, NRX4204 exhibited dramatic effects in the prevention of the development of lung cancer and in the prevention and treatment of breast cancer in spontaneous models. We have initiated a Phase I clinical trial and intend to pursue the development of this compound as a treatment for both lung and breast cancer. There are no rexinoid treatments currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, next-generation rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-looking statements.

CONTACTS: Media

David Schull

(212) 845-4271

david.schull@russopartnersllc.com

Investors

Parag Dave

(917) 322-2585

pdave@otccommunications.com


'/>"/>
SOURCE NuRx Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
3. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
6. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 Amarantus BioScience ... on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today ... be presenting at two upcoming investor conferences: SeeThru ... Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For ... their lives in military battle for the country. The nonprofit Hope For Heroes ... more programs that empower independence for disabled military veterans, as well as police, firemen, ...
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line ... in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than ... by government agencies, including NASA. , In 2012, NASA strategically set up 17 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James ... Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the ... founder of Retina Group of New York , is a Board Certified ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
Breaking Medicine News(10 mins):